• News
  • SAN DIEGO
  • BioTech

FDA accepts NDA submission for carbamazepine IV

Ligand Pharmaceuticals Inc.'s (Nasdaq: LGND) Captisol licensee Lundbeck LLC announced that the U.S. Food and Drug Administration has accepted for review a new drug application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine.

An action letter is anticipated before the end of 2014. Carbella (carbamazepine) Injection is the proposed U.S. trade name.

With acceptance of the NDA filing, San Diego-based Ligand earns a $200,000 milestone payment.

User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11119 N. Torrey Pines Rd. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
93.08
  -2.14  
- 2.25%
292,058,000
112.4
45.61

Insider Trade Data

Date Insider Shares Type Value
08/17/2015 Knott, David M 4,000 Sell $383,937
08/17/2015 Knott, David M 4,000 Sell $383,937
08/13/2015 Knott, David M 50,000 Sell $4,813,782
08/07/2015 Knott, David M 200 Sell $19,803
08/06/2015 Higgins, John L 4,666 Sell $516,946

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology